Search

Position of EHA on Personalized Medicine

 

The challenge
Despite its apparent complexity, personalized medicine could transform healthcare, by tailoring healthcare solutions to the individual patient, delivering ‘the right treatment to the right patient at the right time’ – and helping to get more value from healthcare spending.…

Read more

Congress Sponsor Program

Join us at the EHA Annual Congress, where you have the unique opportunity to connect and grow with a community of hematology experts.

Read more

Does the patient with myelofibrosis feel better through Pacritinib?

Pacritinib is an oral next-generation multikinase inhibitor with specificity for JAK2 and FLT3 being evaluated to treat myelofibrosis in two Phase 3 trials.

Read more

Message from the EHA Board

After more than a decade of tireless work to further EHA’s mission our Executive Director, Carin Smand, has unfortunately announced that she will be leaving our organization.

Read more

EHA-SWG Scientific Meeting on Acquired Aplastic Anemia

EHA & the EHA Scientific Working Group on Granulocyte and Constitutional Marrow Failure Syndromes are happy to announce their recent collaboration in organizing a virtual meeting program on Acquired Aplastic Anemia.

Read more

EU pilot on drug repurposing

Drug repurposing (finding new indications for existing authorized medicines) is increasingly prominent in the debate about improving access to medicines. As stated in EHA’s position paper on access to affordable orphan medicines (Merlini et al.

Read more

Evaluation of 243 patients with deletion 17p chronic lymphocytic leukemia treated with ibrutinib: a cross-study analysis of treatment outcomes

Evaluation of 243 patients with deletion 17p chronic lymphocytic leukemia treated with ibrutinib: a cross-study analysis of treatment outcomes

Chronic lymphocytic leukemia (CLL) with the deletion of chromosome 17p (del17p) has been linked to aggressive disease and patient survival of only…

Read more